文献速递肿瘤 PET/CT核素与放射性配体治疗

神经内分泌肿瘤的分子影像诊疗一体化

Molecular imaging Theranostics of Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2023-01-07

神经内分泌肿瘤(NEN)多为分化良好的神经内分泌肿瘤(NET),高表达生长抑素受体(SSTR),可用[68Ga]-DOTA-肽PET/CT评估病变范围及肽受体放射性核素治疗(PRRT)的适用性。PRRT已被主要科学学会纳入治疗流程,多项新策略与新放射性药物正在评估中。

要点

  • 分化良好的NET高表达SSTR,可用[68Ga]-DOTA-肽PET/CT评估病变范围及PRRT适用性。
  • PRRT现被认为是表达SSTR的NET有效且安全的治疗选择,已纳入主要科学学会的治疗流程。
  • 多项提高PRRT疗效、降低毒性的新策略及新兴放射性药物正在评估中。

核心结论

  • PRRT现被认为是表达SSTR的NET有效且安全的治疗选择,在177Lu-DOTATATE获FDA和EMA批准后已纳入主要科学学会的治疗流程。

研究设计与样本

  • 本文为综述,聚焦NEN诊断与治疗的当前知识及新兴前景。

主要发现

  • NEN罕见且异质,多起源于胃-肠-胰(GEP)道,其次为肺,需多学科讨论以实现最佳诊疗管理。
  • 分化良好的NEN(NET)高表达SSTR,可用[68Ga]-DOTA-肽([68Ga]Ga-DOTANOC、[68Ga]Ga-DOTATOC、[68Ga]Ga-DOTATATE)PET/CT评估病变范围及PRRT适用性。
  • 自90年代中期起,90Y或177Lu标记的SSTR类似物已用于NET治疗。
  • 多项提高PRRT疗效和降低毒性的新策略正在评估中,包括治疗方案个体化、选择最合适患者、改进疗效评估标准、优化治疗顺序、PRRT再治疗可行性、PRRT与其他治疗联合。
  • 多种新兴放射性药物在显像和治疗方面显示令人鼓舞的结果,包括18F标记的SSTR类似物、用于诊断和治疗的SSTR拮抗剂、用于治疗的α核素标记、结合新细胞靶点的放射性药物。

临床怎么用

  • 多学科讨论是NEN最佳诊断和治疗管理的必要条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary discussion is mandatory for optimal diagnostic and therapeutic management. Well-differentiated NEN (NET) present a high expression of somatostatin receptors (SSTR) and can be studied with [68Ga]-DOTA-peptides ([68Ga]Ga-DOTANOC, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE) PET/CT to assess disease extension and the eligibility for peptide receptor radionuclide therapy (PRRT). SSTR-analogues labelled with 90Y or 177Lu have been used since mid-90s for NET therapy. PRRT is now considered an effective and safe treatment option for SSTR-expressing NET: following the approval of 177Lu-DOTATATE by FDA and EMA, PRRT is now part of the therapeutic algorithms of the main scientific societies. New strategies to improve PRRT efficacy and to reduce its toxicity are under evaluation (eg, personalization of treatment schemes, the selection of the most suitable patients, improvement of response assessment criteria, optimization of treatment sequencing, feasibility of PRRT-retreatment, combination of PRRT with other treatments options). Recently, several emerging radiopharmaceuticals showed encouraging results for both imaging and therapy (eg, SSTR-analogues labelled with 18F, SSTR-antagonists for both diagnosis and therapy, alpha-labelling for therapy, radiopharmaceuticals binding to new cellular targets). Aim of this review is to focus on current knowledge and to outline emerging perspectives for NEN's diagnosis and therapy.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fortunati E, Bonazzi N, Zanoni L, et al. Molecular imaging Theranostics of Neuroendocrine Tumors. Semin Nucl Med. 2023. PMID: 36623974. doi:10.1053/j.semnuclmed.2022.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。